TrialLancet (London, England)2013

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

George D Demetri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.